Results 131 to 140 of about 5,547 (244)

Hi Reddit! I am Joseph Glajch, the Director of Analytical Development for Momenta Pharmaceuticals. Ask me anything about biosimilars or what it’s like for chemists to work in the private sector. [PDF]

, 2017
AmerChemSocietyAMA, r Science
openalex   +1 more source

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. [PDF]

, 2018
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic
Beck, Kristen M, Liao, Wilson, Sanchez, Isabelle M, Yang, Eric J   +3 more
core  

Model framework for off label use of medicines [PDF]

, 2016
Background The drug licensing regulatory system ensures that marketed drugs to be used, meet the high standards and requirements for quality, efficacy and safety.
Glavas Dodov, Marija, Koshi, Blerina, Nica, Vasilka, Simonovska Crcarevska, Maja, Slaveska-Raicki, Renata, Zisovska, Elizabeta   +5 more
core  

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

Rheumatology and Therapy
Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Francois Morand, Greg Kricorian, David Collier, Jonathan Kay   +8 more
doaj   +1 more source

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu   +14 more
doaj   +1 more source

Innovation and market dynamics in the EPO market [PDF]

In this paper we study the demand and supply of erythropoietin in four Nordic countries, using an econometric model based on discrete choice and a random utility model.
Sorisio, Enrico, Strøm, Steinar
core  

Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart

Scientific Reports
Biosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape.
Nikhil S. Ghade, Damodar K. Thappa, Jeseena Lona, Archana R. Krishnan, Sanjay M. Sonar   +4 more
doaj   +1 more source

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

, 2014
223 ...
openaire   +1 more source

Understanding the market dynamics of biosimilars

, 2016
Biosimilars represent an attractive market opportunity in the pharmaceutical industry. In order to understand the underlying market dynamics and to identify the success factors of the biosimilars market, a PEST (political, economic, social, technological)
Dassow, J. (Jonas), Daubenfeld, T. (Thorsten), Keßler, M. (Maximilian), Schulze, J. (Jonas)   +3 more
core  

PDG101 TRENDS IN PRICES AND CONSUMPTION OF BRANDED AND GENERIC OR BIOSIMILAR ANTINEOPLASTIC MEDICINES USED FOR SOLID TUMORS TREATMENT IN THE RUSSIAN PHARMACEUTICAL MARKET [PDF]

, 2019
А. В. Никитина, F. V. Gorkavenko, Y. Saybel, M. Avxentyeva, М. В. Сура   +4 more
openalex   +1 more source